TVTX

27.56

2.87% 0.77

Handel nachbörslich: 27.56

Travere Therapeutics Inc (TVTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TVTX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$26.79

Offen:

$26.84

24-Stunden-Volumen:

1.57M

Relative Volume:

0.79

Marktkapitalisierung:

$2.54B

Einnahmen:

$490.73M

Nettoeinkommen (Verlust:

$-50.26M

KGV:

-45.70

EPS:

-0.603

Netto-Cashflow:

$-20.37M

1W Leistung:

+2.23%

1M Leistung:

-6.07%

6M Leistung:

+12.01%

1J Leistung:

+31.18%

1-Tages-Spanne:

$26.50

$27.59

1-Wochen-Bereich:

$26.15

$28.29

52-Wochen-Spanne:

$12.91

$42.13

Travere Therapeutics Inc Stock (TVTX) Company Profile

Firmenname

Travere Therapeutics Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (623)

Telefon

888-969-7879

Adresse

3611 VALLEY CENTRE DR, SAN DIEGO

Mitarbeiter

497

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, ALNY, ARGX, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TVTX Travere Therapeutics Inc	27.56	2.47B	490.73M	-50.26M	-20.37M	-0.603
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-31	Bestätigt	Citigroup	Buy
2025-06-11	Bestätigt	Citigroup	Buy
2025-06-11	Fortgesetzt	H.C. Wainwright	Buy
2025-01-10	Eingeleitet	Cantor Fitzgerald	Overweight
2024-10-21	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-09-09	Hochstufung	Guggenheim	Neutral → Buy
2024-03-27	Herabstufung	Guggenheim	Buy → Neutral
2023-12-05	Hochstufung	Citigroup	Neutral → Buy
2023-11-20	Eingeleitet	Citigroup	Neutral
2023-09-22	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-09-21	Herabstufung	William Blair	Outperform → Mkt Perform
2023-09-06	Fortgesetzt	Evercore ISI	Outperform
2023-07-21	Eingeleitet	JP Morgan	Overweight
2023-06-07	Fortgesetzt	Piper Sandler	Neutral
2023-05-22	Eingeleitet	TD Cowen	Outperform
2023-05-05	Hochstufung	Bryan Garnier	Sell → Neutral
2023-03-01	Eingeleitet	Guggenheim	Buy
2023-02-21	Hochstufung	Wedbush	Neutral → Outperform
2022-12-14	Eingeleitet	Stifel	Hold
2022-12-05	Eingeleitet	Wells Fargo	Overweight
2022-09-21	Eingeleitet	Bryan Garnier	Sell
2022-07-14	Fortgesetzt	Canaccord Genuity	Buy
2022-03-31	Eingeleitet	Piper Sandler	Overweight
2022-02-28	Eingeleitet	H.C. Wainwright	Buy
2021-05-26	Herabstufung	Wedbush	Outperform → Neutral

Alle ansehen

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

11:19 AM

JPMorgan Chase & Co. Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat

11:19 AM

11:08 AM

JP Morgan Lowers Price Target for TVTX to $41.00, Maintains Over - GuruFocus

11:08 AM

02:38 AM

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

02:38 AM

Mar 23, 2026

Travere Therapeutics (TVTX) Gains Attention with Potential FDA A - GuruFocus

Mar 23, 2026

Citi opens ‘upside 90-day catalyst watch’ on Travere Therapeutics - TipRanks

Mar 23, 2026

Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts - MSN

Mar 23, 2026

Mar 21, 2026

Travere Therapeutics (TVTX) reports 144% annual growth in Filspari sales for 2025 - MSN

Mar 21, 2026

Responsive Playbooks and the TVTX Inflection - Stock Traders Daily

Mar 21, 2026

Pullback Watch: Should value investors consider Travere Therapeutics Inc2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 21, 2026